US 12,071,615 B2
Blood cell lysis reagent
Kui Gao, San Diego, CA (US); Jijumon Chelliserry, San Diego, CA (US); and Jeffrey Linnen, Poway, CA (US)
Assigned to Gen-Probe Incorporated, San Diego, CA (US)
Filed by Gen-Probe Incorporated, San Diego, CA (US)
Filed on Sep. 27, 2021, as Appl. No. 17/485,599.
Application 17/485,599 is a continuation of application No. 16/094,070, granted, now 11,162,091, previously published as PCT/US2017/029671, filed on Apr. 26, 2017.
Claims priority of provisional application 62/328,358, filed on Apr. 27, 2016.
Prior Publication US 2022/0002707 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/10 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/70 (2006.01)
CPC C12N 15/1003 (2013.01) [C12Q 1/6806 (2013.01); C12Q 1/70 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A composition comprising a lysis reagent admixed with whole blood,
wherein the reagent comprises (i) sodium phosphate, (ii) lithium lauryl sulfate (LLS) at a concentration of from about 8% (w/v) to about 10% (w/v), (iii) EDTA-Na2 at a concentration of from about 0.5 mM to about 5 mM, and (iv) EGTA at a concentration of from about 0.5 mM to about 5 mM, wherein the reagent has a pH that is greater than 5.5, and wherein the reagent does not include a chloride containing salt; and
wherein the ratio of the reagent to the whole blood is about 4:1.